A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trialCitation formats

  • External authors:
  • Paul Emery
  • Sarah Horton
  • Raluca B Dumitru
  • Kamran Naraghi
  • Desiree van der Heijde
  • Richard Wakefield
  • Elizabeth M A Hensor

Standard

A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial. / Emery, Paul; Horton, Sarah ; Dumitru, Raluca B; Naraghi, Kamran; Heijde, Desiree van der; Wakefield, Richard; Hensor, Elizabeth M A ; Buch, Maya.

In: Annals of the rheumatic diseases, Vol. 79, No. 4, 2020, p. 464-471.

Research output: Contribution to journalArticlepeer-review

Harvard

Emery, P, Horton, S, Dumitru, RB, Naraghi, K, Heijde, DVD, Wakefield, R, Hensor, EMA & Buch, M 2020, 'A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial', Annals of the rheumatic diseases, vol. 79, no. 4, pp. 464-471. https://doi.org/10.1136/annrheumdis-2019-216539

APA

Emery, P., Horton, S., Dumitru, R. B., Naraghi, K., Heijde, D. V. D., Wakefield, R., Hensor, E. M. A., & Buch, M. (2020). A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial. Annals of the rheumatic diseases, 79(4), 464-471. https://doi.org/10.1136/annrheumdis-2019-216539

Vancouver

Emery P, Horton S, Dumitru RB, Naraghi K, Heijde DVD, Wakefield R et al. A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial. Annals of the rheumatic diseases. 2020;79(4):464-471. https://doi.org/10.1136/annrheumdis-2019-216539

Author

Emery, Paul ; Horton, Sarah ; Dumitru, Raluca B ; Naraghi, Kamran ; Heijde, Desiree van der ; Wakefield, Richard ; Hensor, Elizabeth M A ; Buch, Maya. / A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial. In: Annals of the rheumatic diseases. 2020 ; Vol. 79, No. 4. pp. 464-471.

Bibtex

@article{a8e19d5b93b24c3e807fc3dd9e3613c8,
title = "A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial",
abstract = "Objectives: We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable response to first-line ETN+MTX.Methods: Pragmatic, open-label, RCT of treatment-na{\"i}ve ERA (≤12 month symptom), DAS28ESR≥3.2, rheumatoid factor(RF) +/- anti-citrullinated peptide antibody(ACPA) positive, or ultrasound power Doppler(PD) if RF and ACPA negative. Subjects were randomised 1:1 to ETN+MTX; or MTX-TT, escalated to ETN if week 24 DAS28-ESR≥2.6; and intramuscular corticosteroid at protocolised timepoints. Primary endpoint of week 48 DAS28ESR remission with clinical and imaging secondary endpoints.ResultsWe randomised 120 patients, 60 to each arm [71% female, 73% RF/84% ACPA positive, median (IQR) symptom duration 20.3(13.1, 30.8) weeks; mean(SD) DAS28 5.1(1.1)]. Remission rates with ETN+MTX and MTX-TT respectively were 38% vs 33% at week 24; 52% vs 38% at week 48 [odds ratio (OR)(95% CI)=1.6(0.8, 3.5), p=0.211]. Greater, sustained DAS28-ESR remission observed with ETN+MTX vs MTX-TT (42% and 27% respectively; p=0.035). PD was fully suppressed by week 48 in over 90% in each arm. Planned exploratory analysis revealed OR(95% CI) 2.84(0.8, 9.6) of achieving remission after 24 weeks of ETN administered first-line compared to administered post-MTX. Conclusions: Compared to remission rates typically reported with first-line TNFi+MTX versus MTX-TT, we did not demonstrate a larger effect in very ERA. Neither strategy conferred remission in the majority of patients although ultrasound confirmed local inflammation suppression. Poorer ETN response following failure of MTX-TT is also suggested. ",
keywords = "early rheumatoid arthritis, anti-TNF, etanercept, remission, ultrasound",
author = "Paul Emery and Sarah Horton and Dumitru, {Raluca B} and Kamran Naraghi and Heijde, {Desiree van der} and Richard Wakefield and Hensor, {Elizabeth M A} and Maya Buch",
year = "2020",
doi = "10.1136/annrheumdis-2019-216539",
language = "English",
volume = "79",
pages = "464--471",
journal = "Annals of the rheumatic diseases",
issn = "0003-4967",
publisher = "BMJ ",
number = "4",

}

RIS

TY - JOUR

T1 - A pragmatic randomised controlled trial of Very early Etanercept and MTX versus MTX with Delayed Etanercept in RA – the VEDERA trial

AU - Emery, Paul

AU - Horton, Sarah

AU - Dumitru, Raluca B

AU - Naraghi, Kamran

AU - Heijde, Desiree van der

AU - Wakefield, Richard

AU - Hensor, Elizabeth M A

AU - Buch, Maya

PY - 2020

Y1 - 2020

N2 - Objectives: We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable response to first-line ETN+MTX.Methods: Pragmatic, open-label, RCT of treatment-naïve ERA (≤12 month symptom), DAS28ESR≥3.2, rheumatoid factor(RF) +/- anti-citrullinated peptide antibody(ACPA) positive, or ultrasound power Doppler(PD) if RF and ACPA negative. Subjects were randomised 1:1 to ETN+MTX; or MTX-TT, escalated to ETN if week 24 DAS28-ESR≥2.6; and intramuscular corticosteroid at protocolised timepoints. Primary endpoint of week 48 DAS28ESR remission with clinical and imaging secondary endpoints.ResultsWe randomised 120 patients, 60 to each arm [71% female, 73% RF/84% ACPA positive, median (IQR) symptom duration 20.3(13.1, 30.8) weeks; mean(SD) DAS28 5.1(1.1)]. Remission rates with ETN+MTX and MTX-TT respectively were 38% vs 33% at week 24; 52% vs 38% at week 48 [odds ratio (OR)(95% CI)=1.6(0.8, 3.5), p=0.211]. Greater, sustained DAS28-ESR remission observed with ETN+MTX vs MTX-TT (42% and 27% respectively; p=0.035). PD was fully suppressed by week 48 in over 90% in each arm. Planned exploratory analysis revealed OR(95% CI) 2.84(0.8, 9.6) of achieving remission after 24 weeks of ETN administered first-line compared to administered post-MTX. Conclusions: Compared to remission rates typically reported with first-line TNFi+MTX versus MTX-TT, we did not demonstrate a larger effect in very ERA. Neither strategy conferred remission in the majority of patients although ultrasound confirmed local inflammation suppression. Poorer ETN response following failure of MTX-TT is also suggested.

AB - Objectives: We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable response to first-line ETN+MTX.Methods: Pragmatic, open-label, RCT of treatment-naïve ERA (≤12 month symptom), DAS28ESR≥3.2, rheumatoid factor(RF) +/- anti-citrullinated peptide antibody(ACPA) positive, or ultrasound power Doppler(PD) if RF and ACPA negative. Subjects were randomised 1:1 to ETN+MTX; or MTX-TT, escalated to ETN if week 24 DAS28-ESR≥2.6; and intramuscular corticosteroid at protocolised timepoints. Primary endpoint of week 48 DAS28ESR remission with clinical and imaging secondary endpoints.ResultsWe randomised 120 patients, 60 to each arm [71% female, 73% RF/84% ACPA positive, median (IQR) symptom duration 20.3(13.1, 30.8) weeks; mean(SD) DAS28 5.1(1.1)]. Remission rates with ETN+MTX and MTX-TT respectively were 38% vs 33% at week 24; 52% vs 38% at week 48 [odds ratio (OR)(95% CI)=1.6(0.8, 3.5), p=0.211]. Greater, sustained DAS28-ESR remission observed with ETN+MTX vs MTX-TT (42% and 27% respectively; p=0.035). PD was fully suppressed by week 48 in over 90% in each arm. Planned exploratory analysis revealed OR(95% CI) 2.84(0.8, 9.6) of achieving remission after 24 weeks of ETN administered first-line compared to administered post-MTX. Conclusions: Compared to remission rates typically reported with first-line TNFi+MTX versus MTX-TT, we did not demonstrate a larger effect in very ERA. Neither strategy conferred remission in the majority of patients although ultrasound confirmed local inflammation suppression. Poorer ETN response following failure of MTX-TT is also suggested.

KW - early rheumatoid arthritis

KW - anti-TNF

KW - etanercept

KW - remission

KW - ultrasound

U2 - 10.1136/annrheumdis-2019-216539

DO - 10.1136/annrheumdis-2019-216539

M3 - Article

VL - 79

SP - 464

EP - 471

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

SN - 0003-4967

IS - 4

ER -